| Item | Medicine |
|---|---|
| Brand name | Kadcyla |
| Generic name | Trastuzumab emtansine |
| Final report date | 03/07/2018 |
| Target population | HER2-positive, unresectable locally advanced or metastatic breast cancer |
| Comparator | Chemotherapy only |
| ICER | JPY 10 million/QALY and over |
Trastuzumab emtansine (Kadcyla)